BCTXF News and Press, BriaCell Therapeutics From 04/23/19

BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announc...

As presented at the American Association for Cancer Research (AACR) annual meeting:  early efficacy data for the first six advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggest additive or synergistic effects on tumor regression (...

BriaCell Therapeutics and Incyte have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA0012, an anti-PD-1 m...

BERKELEY, Calif., and VANCOUVER, British Columbia, April 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces th...

BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Combination study pairing KEYTRUDA with Bria-IMT is ongoing, with initial efficacy data for the first six patients to be released at AACR Annual Meeting Bri...

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) , a biotechnology company developing targeted, safe treatments for cancer, this morning announced that it has closed the first tranche of a non-brokered private placement of up to 20,000,000 of its common shares, each at a price of C$0.10, for...

Early data of BriaCell’s combination study of lead candidate, Bria-IMT™, with KEYTRUDA ®  (by Merck & Co., Inc.) in advanced breast cancer will be announced at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, on April 3, ...

BERKELEY, Calif. and VANCOUVER, British Columbia, March 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to...

Dr. Rebecca Taub, M.D. and Vaughn C. Embro-Pantalony will be joining the BriaCell board of directors Both additions have extensive experience in the biopharma industry, bringing expert knowledge in the field of clinical oncology Company recently announced a private placement offering th...

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) , a biotechnology company developing targeted, safe treatments for cancer, on Wednesday announced its intention to complete a non-brokered private placement of up to 20,000,000 common shares of the company at a price of C$0.10 each for gross p...